Hematopoiesis News 9.24 June 19, 2018 | |
| |
TOP STORYFish “Umbrella” Protects Stem Cells from Sun Stem cells that make blood cells in fish flourish in the shade provided by a newly discovered cellular “umbrella” that keeps them safe from UV damage. [Press release from Howard Hughes Medical Institute discussing online prepublication in Nature] Press Release | Press Release 2 | Full Article | Video | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers dissected hematopoietic progenitor populations at single cell resolution, deriving an unbiased reference model of transcriptional states in normal and perturbed murine bone marrow. They define the signature of the naive hematopoietic stem cell and find a continuum of core progenitor states. [Nat Cell Biol] Abstract The Wave2 Scaffold Hem-1 Is Required for Transition of Fetal Liver Hematopoiesis to Bone Marrow Investigators demonstrated that the Wiskott-Aldrich syndrome verprolin-homologous protein complex 2 is required for this transition, as complex degradation via deletion of its scaffold Hem-1 causes the premature exhaustion of neonatal bone marrow hematopoietic stem cells. [Nat Commun] Full Article ASXL1/EZH2 Mutations Promote Clonal Expansion of Neoplastic HSC and Impair Erythropoiesis in PMF Hematopoietic stem cells (HSC) from primary myelofibrosis (PMF) patients with double ASXL1/EZH2 mutations exhibited significantly higher engraftment in immunodeficient mice than those from patients without histone modifier mutations. EZH2 mutations correlated with aberrant erythropoiesis in PMF patients, exemplified by impaired maturation and cell cycle arrest of erythroid progenitors. [Leukemia] Abstract Adult Zebrafish Langerhans Cells Arise from Hematopoietic Stem/Progenitor Cells Using a laser-mediated temporal-spatial resolved cell labeling method, scientists demonstrated that most adult Langerhans cells originated from the ventral wall of the dorsal aorta, an equivalent to the mouse aorta, gonads, and mesonephros, where both hematopoietic stem cells (HSCs) and non-HSC progenitors are generated. [eLife] Abstract | Download Full Article Researchers showed that iron overload impairs the frequency and colony-forming capacity of normal hematopoietic stem and progenitor cells, especially in erythroid, in myelodysplastic syndrome mice, which at least in part, due to growth differentiation factor 11 induced reactive oxygen species and shortening survival of myelodysplastic syndrome mice. [Haematologica] Abstract | Full Article Using an affordable and convenient method, investigators demonstrated that the administration of fludarabine promotes the extensive and rapid engraftment of human normal hematopoiesis in immunodeficient mice. Quantification of human CD45+ cells in bone marrow revealed approximately a 102-fold increase in mice conditioned with irradiation plus fludarabine. [Sci Rep] Full Article Trim27 Confers Myeloid Hematopoiesis Competitiveness by Up-Regulating Myeloid Master Genes The authors investigated the roles of Trim27 in hematopoiesis by enforcing its expression in mouse and human hematopoietic stem and progenitor cells (HSPC). Ectopic expression of Trim27 in mouse fetal liver HSPC conferred repopulating advantage with myeloid dominance. [J Leukoc Biol] Abstract Researchers examined the impact exposing human hematopoietic stem/progenitor cells to microgravity had upon their capacity to repair DNA damage and their ability to generate immune cells critical for mounting an effective anti-tumor response. [Stem Cells Dev] Abstract Establishment of a Cell Model of X-Linked Sideroblastic Anemia Using Genome Editing Using a genome editing system, a mutation was introduced in the erythroid-specific enhancer of the ALAS2 gene in HUDEP2 cells, which were derived from human umbilical stem cells and can produce erythrocytes. The established cell line, termed HA2low, expressed less ALAS2 mRNA than did wild-type cells, even after erythroid differentiation. [Exp Hematol] Abstract CLINICAL RESEARCHSince there is a steep dose-response effect for intravenous melphalan, investigators evaluated an alternative single autologous transplantation strategy using higher-dose melphalan at 280 mg/m2 (MEL 280) with amifostine as a cytoprotectant as the maximum tolerated dose determined in an earlier Phase I dose escalation trial. [Bone Marrow Transplant] Abstract | |
| |
REVIEWSThe authors discuss the mechanisms of T and NK-cell immune evasion that facilitate relapse of hematological malignancies after allogeneic stem cell transplantation, and explore emerging strategies to augment the allogeneic immune system in order to construct a more potent graft versus tumor response. [Bone Marrow Transplant] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSDaiichi Sankyo Company, Limited announced that positive results from the pivotal QuANTUM-R Phase III study of single agent quizartinib were presented as a late-breaking oral presentation. [Press release from Daiichi Sankyo Company, Limited discussing research presented at the 23rd Congress of the European Hematology Association (EHA), Stockholm] Press Release Cellerant Therapeutics, Inc. presented results from its randomized controlled Phase II clinical trial of CLT-008 (romyelocel-L, human myeloid progenitor cells), an off-the-shelf cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. [Press release from Cellerant Therapeutics, Inc. (Business Wire, Inc.) discussing research presented at the 23rd Congress of the European Hematology Association (EHA), Stockholm] Press Release Aprea Therapeutics presented results from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS. [Press release from Aprea Therapeutics discussing research presented at the 23rd Congress of the European Hematology Association (EHA), Stockholm] Press Release bluebird bio, Inc. announced new interim data from the ongoing HGB-206 Phase I multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease will be presented in an oral presentation. [Press release from bluebird bio, Inc. discussing research presented at the 23rd Congress of the European Hematology Association (EHA), Stockholm] Press Release Amphivena Demonstrates First Human Proof-of-Concept for AMV564 in Relapsed/Refractory AML Amphivena Therapeutics highlighted initial data from the dose-escalation portion of the First-in-Human Phase I trial (AMV564-101, NCT03144245) evaluating AMV564 in patients with relapsed and/or refractory acute myeloid leukemia (AML) in an oral presentation. [Press release from Amphivena Therapeutics (Business Wire, Inc.) discussing research presented at the 23rd Congress of the European Hematology Association (EHA), Stockholm] Press Release | |
| |
INDUSTRY NEWSSickle Cell Disease Association of America, Inc. Partners with Emmaus Life Sciences, Inc. The Sickle Cell Disease Association of America, Inc. and Emmaus Life Sciences, Inc. have announced a new partnership involving national awareness and patient education initiatives to address the complications of sickle cell disease. [Emmaus Life Sciences, Inc. (Business Wire, Inc.)] Press Release Trovagene, Inc. announced completion of the first dose cohort of PCM-075, a highly-selective polo-like kinase 1 inhibitor, in combination with decitabine, in its Phase Ib/II clinical trial in patients with acute myeloid leukemia (AML). [Trovagene, Inc.] Press Release | |
| |
POLICY NEWSHouse Bill Gives NIH a 3% Boost in 2019, to $38.3 Billion A draft bill released by a House of Representatives spending panel would give the National Institutes of Health (NIH) in Bethesda, Maryland, a $1.25 billion raise in 2019, to $38.3 billion. That is 3% more than this year’s level and $4.1 billion more than President Donald Trump’s administration had requested. [ScienceInsider] Editorial New Zealand Appoints First Female Chief Scientific Adviser The New Zealand government has appointed biochemist Juliet Gerrard as its next chief scientific adviser — the first woman to hold the position. [Nature News] Editorial U.S. Legislators Back Larger Facilities Budget for NSF The National Science Foundation (NSF) in Alexandria, Virginia, is in line for a budget increase of 4% to 5% next year. That assessment is based on bills approved recently by the spending committees in both chambers of Congress. Lawmakers have also signaled support for growing the account that NSF uses to build major new scientific facilities. [ScienceInsider] Editorial Why the Medical Research Grant System Could Be Costing Us Great Ideas The medical research grant system in the United States, run through the National Institutes of Health, is intended to fund work that spurs innovation and fosters research careers. In many ways, it may be failing. [The New York Times] Editorial
| |
EVENTSNEW 7th Annual International Symposium on Regenerative Rehabilitation Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Technologist – Hematopoietic (STEMCELL Technologies Inc.) NEW Research Fellow – Epigenetics and Hematology (University of Edinburgh) Postdoctoral Fellow – Leukemogenesis (Erasmus Medical Center Cancer Institute) Postdoctoral Scientist – Stem Cell Biology (University of Oxford) Postdoctoral Research Scholar – Hematologic Malignancies (Washington University School of Medicine) Cancer Researchers – Hematologic Malignancy (Cedars-Sinai Medical Center) Postdoctoral Fellow – Hematopoiesis and Leukemia (University of Pennsylvania) Postdoctoral Position – Stem Cell and Cancer Research (Institute for Research in Biomedicine) Postdoctoral Fellow – Stem Cells, Development & Cancer (Albert Einstein College of Medicine) Postdoctoral Research Associate – Mechanisms of Leukemia (University of Virginia) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|